Dapagliflozin (DAP) is indicated for the management of diabetes mellitus Type 2, and functions to improve glycemic control in adults when combined with diet and exercise1. DAP is an inhibitor of sodium-glucose cotransporter 2 (SGLT2) responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. By inhibiting SGLT2, DAP reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion2. In present work, a selective, specific, sensitive and economical UV spectroscopic method has been developed for the estimation of Dapagliflozin in Bulk and its pharmaceutical dosage forms. An absorption maximum was found to be at 233.65 nm. Dapagliflozin obeyed Beer’s law in the concentration range from 10-35 μg / ml. Proposed method was validated according to ICH guidelines and values of accuracy, precision and other statistical analysis were found to be in good accordance with the prescribed values with correlation coefficient of 0.9998. The percentage recovery of Dapagliflozin ranged from 99.7 in pharmaceutical dosage form. Results of the analysis for accuracy, precision, LOD, LOQ and were found to be satisfactory. The proposed method is simple, rapid and suitable for the routine quality control analysis.